REGULATORY

• Japan PM Vows Early Kick Off of Off-Year Revision Debate at Chuikyo
  March 29, 2024

• Japan Diet Passes FY2024 Budget, Record Social Security Spending
  March 29, 2024

• MHLW Generic Panel Outlines Plan to Drive Industry Revamp within Specific Time Frame
  March 28, 2024

• Japan’s HIV, AIDS Cases Rebound in 2023 after COVID
  March 28, 2024

• Japan Govt Launches Panel to Respond to Red Yeast Rice Issue
  March 28, 2024

• Japan Approves Piasky, Beyfortus, Broader Use for Abrysvo, and Lot More
  March 27, 2024

• PMDA Chief Fujiwara to Remain Skipper for Another Term
  March 27, 2024

• PMDA to Build Shared Database of GMP Inspection Reports
  March 26, 2024

• Japan Shelves Decision on SanBio’s Lead Cell Therapy on Quality Concerns
  March 26, 2024

• Japan’s 1st Eylea Biosimilar Approval on Horizon? JAN Now Decided
  March 25, 2024

• Chuikyo Agrees to Exempt PD-1/PD-L1, JAK Classes from Spillover Re-Pricing
  March 25, 2024

• Xocova’s Price to Remain Intact after Full Approval, No Change in Clinical Positioning
  March 25, 2024

• Japan Set to Push Central IRBs for Clinical Trials, Avoid Customary All-Case PMS
  March 22, 2024

• Pharma Regulation Panel Wraps Up Debate, Report to Be Finalized Soon
  March 22, 2024

• 1 Year on, China Mulling Potential Indictment of Detained Astellas Employee
  March 22, 2024

• Japan Awards Orphan Tag to Janssen’s Talquetamab, 2 More APIs
  March 22, 2024

• Japan Resumes Debate on Rx-to-OTC Switch of PPIs after Over 5 Years
  March 22, 2024

• New LDP Project Team Launched to Boost Global Access to Infectious Disease Drugs
  March 21, 2024

• Industry Explains Scheme to Deal with New Self-Inspection Asked for All Generic Makers
  March 19, 2024

• Japan Mulls Simplifying Drug Delisting Process to Help Ensure Stable Supplies
  March 19, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 52
• 53
• 54
• 55
• 56
• 57
• 58
• 59
• 60
• …
• Next ›
• 最終 »